Smoldering multiple myeloma is an asymptomatic, precancerous condition with abnormal plasma cells and elevated monoclonal protein levels. Smoldering multiple myeloma is a complex, intermediary stage ...

Recently, new immune-based treatments have shown impressive results when multiple myeloma returns, changing how doctors treat ...

D-VRd is the only quadruplet regimen approved for patients with newly diagnosed multiple myeloma, irrespective of transplant ...

New draft guidance from the FDA on multiple myeloma endpoints reflects the new technology available to assess disease and how patient journeys have changed with better treatments.

The FDA approved Darzalex Faspro with Velcade, Revlimid and dexamethasone for newly diagnosed multiple myeloma ineligible for ...

The MajesTEC-9 trial showed a 40% reduced risk of death and a 71% reduced risk of disease progression or death with teclistamab. Teclistamab was approved to treat relapsed/refractory multiple myeloma ...

Real world data show multiple myeloma survival varies by treatment line and autologous stem cell transplant status. Read more ...

In certain cases, regulators will now be open to clearing therapies based on their ability to eliminate tumor cells, a change ...

Men are twice as likely as women to have stage III multiple myeloma at diagnosis and appear to have a greater tumor burden than women, according to ...

While it’s not as well-known as, say, leukemia or melanoma, multiple myeloma is the second most common blood cancer in adults, according to the Cancer Research Institute. “Multiple myeloma is a cancer ...